Key result
Low doses (10^2 to 10^3 HAD50) of recombinant ASFV-G-Δ9GLv protected swine against lethal challenge with parental ASFV-G, with complete protection observed at 28 days postvaccination.
Population
Swine (pigs) and primary swine macrophages
Comparison
Genetically modified ASFV-G strain harboring a… vs Parental ASFV-G (homologous challenge)
Design
Preclinical
Follow-up
21 to 28 days
Authors
Loading...
First ASFV-G vaccine candidate protects pigs from lethal challenge; leaves open commercial development pending safety and field trials.
A genetically modified ASFV-G strain lacking the 9GL gene provides effective protection against homologous lethal challenge in swine when administered at low doses.
O’Donnell et al. (2015) studied African swine fever. ASFV-G-Δ9GLv vs. Parental ASFV-G was evaluated on Protection against lethal disease upon homologous challenge. Low doses (10^2 to 10^3 HAD50) of recombinant ASFV-G-Δ9GLv protected swine against lethal challenge with parental ASFV-G, with complete protection observed at 28 days postvaccination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: